Claims for Patent: 8,765,172

Summary for Patent: 8,765,172

Title:	Acoustically sensitive drug delivery particles comprising non-lamellar forming lipids
Abstract:	Novel acoustically sensitive drug carrying particles comprising non-lamellar forming lipids are disclosed, as well as uses and methods thereof. The drug carrying particles accumulate in the diseased target tissue and efficiently release their payload upon exposure to acoustic energy.
Inventor(s):	Lauten; Cecilia Leal (Oslo, NO), Rognvaldsson; Karen Sibylla (Oslo, NO), Fossheim; Sigrid L. (Oslo, NO), Nilssen; Esben A. (Oslo, NO), Evjen; Tove J. (Oslo, NO)
Assignee:	Epitarget AS (Oslo, NO)
Application Number:	12/747,123
Patent Claims:	1. A sonosensitive particulate material, comprising: more than 10 mol % phosphatidylethanolamine (PE) with an acyl chain of 18 carbon atoms or longer and/or more than 10 mol % phosphatidylcholine (PC) with an acyl chain of 20 carbon atoms or longer; polyethylene glycol (PEG) or a derivative thereof; and a drug, said material comprising no undissolved gases, wherein the head group of said PE is not conjugated to PEG or a derivative thereof. 2. The material of claim 1, comprising 47 mol % or more of said PE and/or PC. 3. The material of claim 1, wherein the PE or PC is an unsaturated phospholipid. 4. The material of claim 1, wherein the PE is 1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine (DSPE), 1-Stearoyl-2-Oleoyl-sn-glycero-3-Phosphoethanolamine (SOPE), 1-Palmitoyl-2-Oleoyl-sn-glycero-3-Phosphoethanolamine (POPE), and/or 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine (DOPE), and the PC is eicosenoyl PC, erucoyl PC, and/or nervonoyl PC. 5. The material of claim 1, wherein the PE is Dioleoyl-sn-Glycero-3-Phosphoethanolamine (DOPE) and the PC is erucoyl PC. 6. The material of claim 1, further comprising a primary alcohol comprising 2-20 carbon atoms. 7. The material of claim 6, wherein the primary alcohol is propanol, butanol, hexanol, heptanol, or octanol or any combination thereof. 8. The material of claim 6, wherein the primary alcohol is hexanol. 9. The material of claim 1, further comprising cholesterol. 10. The material of claim 1, wherein the particulate material is a liposome. 11. The material of claim 1, wherein a size of said material is less than 200 nm. 12. A method for treating a condition or disease, comprising: administering the sonosensitive particulate material of claim 11, wherein said drug is activated or released by acoustic energy. 13. The method of claim 12, wherein the disease or condition is the cancer, immune disorders, infections, or inflammatory diseases. 14. The material of claim 1, wherein said material is suitable for medical use. 15. A pharmaceutical composition comprising the material of claim 1. 16. The material of claim 1, wherein a size of said material falls within the range 50 to 150 nm. 17. The material of claim 1, wherein the drug is doxorubicin, elacytarabine, aldesleukin, filgrastim, pegfilgrastim, or sargramostim. 18. The material of claim 1, said material comprising more than 10 mol % PE with an acyl chain of 18 carbon atoms or longer and more than 10 mol % PC with an acyl chain of 20 carbon atoms or longer, wherein the head group of said PE is not conjugated to PEG or a derivative thereof. 19. The material of claim 18, comprising 47 mol % or more of said PE and PC.

Details for Patent 8,765,172

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Clinigen, Inc.	PROLEUKIN	aldesleukin	For Injection	103293	05/05/1992		2027-12-10
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	02/20/1991		2027-12-10
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	06/28/2000		2027-12-10
Partner Therapeutics, Inc.	LEUKINE	sargramostim	For Injection	103362	03/05/1991		2027-12-10
Partner Therapeutics, Inc.	LEUKINE	sargramostim	Injection	103362	03/05/1991		2027-12-10